# TRITON (NCT06008093)

> A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06008093
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: Durvalumab; Tremelimumab; Pemetrexed; Pembrolizumab; Carboplatin; Cisplatin
- Enrollment: 103
- Primary outcome: Progression-free survival (PFS) in randomized participants
- Primary outcome: PFS at 6 months
- Primary outcome: PFS at 12 months

## Commentary we found

- X threads: 5

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=triton-nct06008093